Surgeon Calls PowerPort Catheter Infection Warnings Inadequate in Federal Trial

Why It Matters

The case could force stricter FDA labeling requirements and drive manufacturers to redesign ports, impacting patient safety and liability costs across the medical‑device sector.

Key Takeaways

• Bard’s PowerPort IFU lists infection as “possible complication,” not warning.
• Infection rate for port catheters is roughly 14% per clinical data.
• Internal Bard documents label chronoflex material “dirt” and note cracking risk.
• Plaintiff’s sepsis delayed chemotherapy, highlighting patient safety stakes.
• Trial underscores industry-wide lack of infection-rate disclosures in device IFUs.

Pulse Analysis

Port catheters are a mainstay for delivering chemotherapy, yet they carry a notable infection risk that can jeopardize treatment timelines. Clinical studies estimate a 14% infection rate for implanted ports, a figure that is often omitted from manufacturer instructions for use (IFUs). This omission creates a knowledge gap for physicians and patients, who may underestimate the need for stringent aseptic protocols during at‑home handling or hospital care. The regulatory landscape currently allows such risks to be listed under generic “possible complications,” limiting the visibility of critical safety data.

The ongoing federal trial against Becton, Dickinson & Company and its Bard subsidiary brings these labeling shortcomings into sharp focus. Expert testimony highlighted that Bard’s IFU fails to quantify infection likelihood and that internal documents label the proprietary chronoflex material as “dirt,” acknowledging its susceptibility to microscopic cracking that fosters bacterial colonization. Such admissions suggest the company was aware of the heightened risk yet did not amend its warnings. The plaintiff’s experience—sepsis, a six‑day hospitalization, and a two‑week chemotherapy delay—underscores the tangible patient harm that can arise from insufficient disclosures.

If the jury finds Bard liable, the decision could trigger a wave of regulatory scrutiny, prompting the FDA to tighten labeling standards for implantable devices. Manufacturers may be compelled to provide explicit infection‑rate data, redesign materials, or develop enhanced patient‑education kits for home de‑access. For investors and industry stakeholders, the case signals potential cost escalations related to litigation, product redesign, and compliance, while also opening opportunities for innovators offering safer catheter technologies.